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Abstract
Conventional molecular and genetic methods for studying cancer are limited to the analysis of one locus at a time.
A cluster of genes that are regulated together can be identified by DNAmicroarray, and the functional relationships
can uncover new aspects of cancer biology. Breast cancer can be used to provide a model to demonstrate the
current approaches to the molecular analysis of cancer. Meta-analysis is an important tool for the identification and
validation of differentially expressed genes to increase power in clinical and biological studies across different sets of
data. Recently, meta-analysis approaches have been applied to large collections of microarray datasets to investigate
molecular commonalities of multiple cancer types not only to find the common molecular pathways in tumour
development but also to compare the individual datasets to other cancer datasets to identify new sets of genes.
Several investigators agree that microarray results should be validated.One commonly used method is quantitative
reverse transcription PCR (qRT-PCR) to validate the expression profiles of the target genes obtained through
microarray experiments. qRT-PCR is attractive for clinical use, since it can be automated and performed on fresh
or archived formalin-fixed, paraffin-embedded tissue samples. The outcome of these analyses might accelerate the
application of basic research findings into daily clinical practice through translational research and may have an
impact on foreseeing the clinical outcome, predicting tumour response to specific therapy, identification of new
prognostic biomarkers, discovering targets for the development of novel therapies and providing further insights
into tumour biology.
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INTRODUCTION
Components and behaviours of biological systems
can be studied using the many tools of genomics,
such as SNPs [1, 2], CGH [3], SSH [4], SAGE [5, 6],
proteomics [7] and siRNA technology [8]. It is
widely believed that functional genomics will trans-
form our understanding of the mechanisms under-
lying cellular function, and in combination with
bioinformatics promises to accelerate the application
of basic discoveries into clinical practice despite the
natural cautions associated with the implementation
of new technologies in the clinical arena.
The human genome sequence is now available
and we have started to understand genomic com-
plexity at the DNA and gene expression levels. The
development of new technologies for the large-scale
analysis of the genome, transcriptome, proteome and
metabolome has enabled functional genomics to
have a profound impact on clinical medicine [9, 10].
An astounding amount of molecular data resulting
from rapid usage of these techniques have accumu-
lated and a multitude of sophisticated methods and
algorithms have been developed for comprehensive
analysis of these data [11].
The application of genomics technologies to the
study of cancer is rapidly shifting toward the analysis
of clinically relevant samples derived from patients
to discover new biomarkers for early detection of
cancers. Since characteristic patterns of gene expres-
sion can be measured in parallel by using microarrays,
gene expression profiling with DNA microarrays
has emerged as a powerful approach to study the
transcriptome of individual cancers. Molecular biol-
ogists work with clinicians and pathologists to obtain
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samples from patients with a known medical history,
so that the molecular characteristics of samples can
be correlated with the clinical presentation. This
approach provides an insight into molecular mechan-
isms of the different cancer types, and also helps to
find novel cancer biomarkers.
There are several published studies that highlight
the remarkable impact of DNAmicroarrays on cancer
research [12–18]. For example, gene expression sig-
natures for the major cancer types and the correlation
with various tumour characteristics that determine
tumour grade or differentiation,metastasis and survival
have been identified through these studies [19–22].
MOLECULAR PROFILING
OF BREASTCANCER
Breast cancer is a major problem in developed coun-
tries and the different classifications of this disease
are mostly based on clinical and pathological factors,
which unfortunately fail to reflect the heterogeneity
of the tumours. There are some histological markers
available to decide on the prognosis and treatment
of breast cancer. Estrogen receptor (ER) status, as
ER-positive or ER-negative, helps to categorize
breast cancers into two major classes. ERBB2
(Her-2/Neu) is also routinely used to classify breast
cancer into HER-2 amplified or non-amplified
categories. There are other single gene markers
such as TP53, and cell proliferation markers such
as Ki-67, and cyclin D1 that have emerged from
detailed molecular analysis [23].
While conventional methods were restricted to
studying a single locus, current high-throughput
techniques have allowed monitoring gene expression
or copy number levels of almost all known genes in a
single experiment. Molecular profiling has been
shown to be well-suited to phenotypic characteriza-
tion of breast cancer and potentially to discover new
molecular classes among cancers with similar histo-
pathological appearance [24–29]. Several landmark
microarray studies have demonstrated that one can
build a molecular taxonomy of breast tumours using
this technology and can provide a more sophisticated
molecular picture together with individualized recur-
rence risks.
Distinguishing tumours on the basis of
their gene expression profiles: impact
on the future of breast cancer research
Gene expression profiling using DNA microarrays
has provided an opportunity to perform more
detailed and individualized breast tumour character-
ization leading to classification of breast cancer
into distinct new molecular subgroups [30]. The
potential advantages of improving tumour classifica-
tion by expression profiling has been central to
several large-scale breast cancer studies over the
past few years that have reported identification of
signature gene lists with potential for prediction
of clinical outcome [24, 25, 29, 31, 32].
One of the first comprehensive studies classifying
sporadic breast tumours into subtypes distinguished
by differences in their expression profiles was
performed by Perou et al. [33]. Using 40 tumours
and 20 matched pairs of samples they identified an
‘intrinsic gene set’ of 476 cDNAs and then used this
to cluster and segregate the tumours into four major
subgroups: a ‘luminal-like cells’ group expressing
ER; a ‘basal-like cells’ group expressing cytokeratins
5 and 17, integrin 4 and laminin, but lacking ER
expression; an ‘ERBB2-positive’ group, and a
‘normal like’ epithelial group [33]. Subsequent
studies confirmed that there are large-scale gene
expression differences between ER-positive (mostly
luminal-like) and ER-negative (mostly basal-like)
cancers and suggested that further molecular subsets
also exist [28, 34, 35]. The prognosis and chemo-
therapy sensitivity of the different subgroups are
different. The luminal type cancers tend to have the
most favourable long-term survival, whereas basal-
like and ERBB2-positive tumours are more sensitive
to chemotherapy [24, 36].
van’t Veer et al. have used DNA microarray
analysis on the primary breast tumours of 78 lymph
node-negative young patients and compared the
expression profiles of 34 patients who developed
distant metastasis within 5 years and 44 patients who
remained disease-free for at least 5 years [25]. Their
analysis led to the identification of a 70-gene
expression signature that was developed to classify
tumours into the good and poor prognosis groups.
The results were later confirmed in a larger set
of tumours [26, 37]. The genes significantly
up-regulated in the poor prognosis signature
included those involved in cell cycle, invasion and
metastasis, angiogenesis and signal transduction. This
70-gene marker set is now commercially available on
the MammaPrint array (Agendia BV, Amsterdam,
The Netherlands) and the prospective MINDACT
clinical trial is underway to evaluate whether use
of the 70-gene classifier is associated with clinical
benefit.
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Wang et al. reported a promising study showing
the use of DNA microarray data for improving risk
assessment for patients with lymph node-negative
breast cancer. The investigators identified a diag-
nostic test based on expression values from a set of
76 genes. They specified 76 genes (60 genes for
ER-positive, 16 for ER-negative breast tumours)
that distinguished lymph node-negative patients
who developed distant metastasis within 5 years
[38]. The genes included in this prognostic signature
belong to many functional classes, including tran-
scriptional regulation, immune response, cell death,
cell cycle, growth and proliferation, suggesting
that different pathways can influence disease pro-
gression [38].
Paik et al. [39] used a different approach to show
the clinical utility of the OncotypeDx classifier of
prognosis for node-negative, ER-positive patients
who received tamoxifen following local therapy
for primary breast cancer. It analyses the expression
of a panel of 21 genes, including ER mRNA,
downstream ER-regulated genes, HER2 and
proliferation-related gene expression levels, which
can help in the diagnosis of ER-positive breast
cancer that can be treated with tamoxifen [39].
These studies show that the molecular classifica-
tion of breast cancer may have an impact on the
prognosis and prediction, and provide further
insights into tumour biology, providing information
to both clinicians and scientists. The molecular
signatures that define particular groups may lead to
the discovery of new therapeutic targets and
treatments that are effective in particular molecular
subsets.
The power of joint analysis of
microarray datasets: meta-analysis
The extensive use of DNA microarray technology in
the characterization of the cell transcriptome is
leading to an ever-increasing amount of microarray
data from cancer studies. Different datasets for the
same type of cancers are available from different
microarray studies and this allows the researchers to
carry out a more comprehensive analysis of their
existing dataset. Besides individual microarrays,
meta-analysis can be used to gather and process the
datasets from multiple cancer types to investigate
common molecular pathways [40–42].
Microarray datasets can be obtained from various
public gene expression data repositories including
the Stanford Microarray Database (SMD) [43],
the National Cancer Institute’s Gene Expression
Omnibus (GEO) [44] and Oncomine [45]. These
databases enable researchers to retrieve and perform
analyses on various microarray experiments from
different laboratories.
Since all cancer cells share some common
characteristics such as loss of growth control, invasion
and metastasis, it is very important to identify
universal cancer type-independent signatures to
better understand cancer pathogenesis and ultimately
to improve therapeutic options. Rhodes et al. applied
the meta-analysis approach to 21 published cancer
microarray datasets, spanning 12 distinct cancer types
and identified a set of 67 genes that are universally
activated relative to corresponding normal tissues in
most cancer types [40].
Collection of independent microarray datasets
generated with the common objective of identifying
differentially expressed genes in a certain type
of cancer has also been performed for breast cancer
[46–48]. These types of studies have resulted in the
identification of gene sets with a high diagnostic
value. In a microarray study with invasive ductal
carcinoma samples, a reliable set of 10 genes were
identified that can be used as a diagnostic tool for
accurate determination of ER status and to make a
decision regarding the endocrine therapeutic strate-
gies for breast cancer. The robustness and reliability
of these classifiers was confirmed after further testing
on three independent microarray gene expression
datasets [49].
Meta-analysis approach can provide novel
candidates not present in the existing literature
allowing reports of multiple genes when neither
dataset can report them when analysed individually
[50, 51].
Large-scale real-time quantitative
reverse transcription PCR (qRT-PCR)
Microarray studies allow high-throughput analysis of
expression for thousands of genes and add valuable
data to tumour studies. However, once cancer target
genes have been identified through this technology,
validation of existing microarray data becomes
inevitable.
qRT-PCR, also known as real-time PCR, plays
an increasingly important role in high-throughput
testing of existing microarray data [52]. qRT-PCR is
an accurate and sensitive method quantifying
mRNA transcripts that uses the quantitative relation-
ship between the amount of starting target sample
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and the amount of PCR product at any given PCR
cycle number. The method allows the detection of
amplicon accumulation since it is performed using
sensitive fluorogenic Taq-Man Probes, molecular
beacons, and scorpions or more sensitive but less
specific intercalating dyes like SYBR Green I which
only fluoresce intensely when associated with
double-stranded DNA [53]. The amount of fluo-
rescence produced from the fluorogenic probes is
measured at each amplification cycle. qRT-PCR has
the advantages of requiring smaller quantities of
sample and producing fast, accurate and easily
reproducible quantitative results with little manip-
ulation of the samples [54].
qRT-PCR is attractive for clinical use since it can
be automated and performed on fresh or archived
formalin-fixed, paraffin-embedded (FFPE) tissue
samples [55, 56]. The biological classification
formed using microarray data has been validated
with freshly frozen breast tissues from multiple
patient cohorts by qRT-PCR. Sorlie et al. [57]
validated and characterized two previously defined
clinically relevant subtypes of early stage breast
carcinomas, luminal A and basal-like, by using
three different microarray platforms. The set of 54
predictor genes identified in this study were validated
by qRT-PCR using the RNA isolated from the
same fresh frozen breast tumour samples that were
used in microarray platforms. These genes were
defined as potential prognostic molecular markers
for these subtypes of breast cancer [57]. Perreard
et al. [58] used the power of qRT-PCR to make
the clinical distinction between ER-positive and
ER-negative breast tumours and identified additional
subtypes of breast tumours that have prognostic
value. In another study, the results obtained with a
70-gene expression profile described previously in
breast cancer [25] were reproduced with qRT-PCR
by using a different set of frozen breast cancer
samples [59]. Urban et al. [60] used two different
microarray platforms and qRT-PCR in their study
and identified the uPA gene associated with distant
metastasis-free survival in ErbB2-positive breast
tumours that can be used as a powerful prognostic
indicator.
Recently, an exhaustive analysis of popular
microarray platforms by the multi-centre consor-
tium, the MicroArray Quality Control (MAQC)
consortium, delivered reassuringly impressive results
for the accuracy and reproducibility of commonly
used microarray platforms [61]. The focus on their
study has been the identification of common
transcripts that are mutually represented among the
various microarray platforms included in the analysis.
Based on the MAQC dataset, Canales et al. [55] used
three different RT-PCR methods to profile the
same RNA samples to determine the concordance
between the microarray-based measurements and
RT-PCR results. They found that the correlation
coefficients were very high for several hundred genes
examined with both methods.
FFPE tissue samples are well-suited for qRT-
PCR expression studies [62]. It has been shown that
it is feasible to extract and purify RNA from FFPE
tissue and to perform gene expression experiments
although fragmentation of RNA can occur during
the fixation process [56]. Retrospective clinical
studies generally use FFPE tissue, as it is the most
widely available material. These tissues have been
used extensively and provide a major resource for
understanding disease mechanisms and using
the power of differentially expressed genes to
evaluate possible new diagnostic or therapeutic
approaches.
A diagnostic assay, OncotypeDXTM (Genomic
Health Inc., Redwood City, CA, USA), has been
developed as an RT-PCR-based assay performed
with FFPE tumour tissue. It analyses the expression
of a panel of 21 genes, which can help in the
diagnosis of ER-positive breast cancer [39]. The
genes identifying molecular subtypes of breast cancer
with prognostic significance obtained from micro-
arrays with fresh-frozen tissues were also used to
diagnose biological subtypes of breast cancer in FFPE
tissues by qRT-PCR. The subtype classifications of
the breast tumour with the diagnostic gene set were
highly comparable between FF and FFPE tissue
samples [63]. Collectively, these studies show the
reproducibility of microarray data with the qRT-
PCR technique.
Although limited to quantification of mRNA
transcripts, the sensitivity, reproducibility, expand-
ability and cost-effectiveness of qRT-PCR make
it a benchmark technology for integration with
microarray technology.
CONCLUDING REMARKS
Recent advances in genomics and genomic technol-
ogies have made it possible to study cancer in many
novel ways. Microarray technology has been used
to study all aspects of cancer biology that help
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to uncover the molecular mechanism of cancer
development and has an impact on diagnosis,
prognosis, drug responses and new therapeutic
approaches in cancer. Another important aspect in
cancer studies is establishing the epigenetic profile of
a cancer type, since modification of proteins
associated with chromatin and methylation of CpG
sites in the DNA has a profound effect on gene
expression. Such studies defining methylation
signature could not only help staging of cancer
cases but also help to identify the potential mole-
cular markers for early cancer detection, assess
cancer risk and improve monitoring of cancer
prognosis. New genome-wide, high-throughput
tools, such as Chromatin-immunoprecipitation
(ChIP)-on-microarray (or ChIP–Chip) are also
becoming very useful for studying epigenetic
modifications in cells. ChIP combined with high-
resolution microarray analysis allows the examination
of genome-wide nucleosome occupancy and histone
modification status [64]. Genome-wide chromatin
status can then be compared with global gene
expression patterns to reveal connections between
specific patterns of histone modifications and the
resulting gene expression in the normal or malignant
phenotype of a cell. Genomic studies exami-
ning tumour sets with multiple complementary
technologies, including comparative genomic hybri-
dization (CGH), single nucleotide polymorphisms
(SNPs), serial analysis of gene expression (SAGE),
ChIP–chip data, proteomics and gene expression
array can provide a multitude of opportunities for
cancer research. The large amount of discoveries
by these high-throughput techniques could then be
integrated with emerging bioinformatics to increase
our knowledge in cancer development. Combining
the results of these multidisiplinary approaches will
contribute to a better biological understanding of,
and, therefore, to the improvement of the clinical
management of cancer.
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